Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Development of a serological microfluidic assay for the rapid detection of interferons in COVID-19 patients
EF 2021-22
Résumé
Antibodies are a natural immune response developed by the body to protect against infection, but in some cases, individuals can develop autoantibodies that attack components of the individual's own body. As such, a dysfunctional immune response can result in an increased susceptibility to infection. In the case of COVID-19 patients, autoantibodies that attack immune system's hormones, like interferons, can result in life-threatening and critical COVID-19 infections. Therefore, the detection of these autoantibodies is critical in managing a patient's prognosis and monitoring for critical infections to protect those at the highest risk. Current testing methods are done in batch groupings and lack accessibility. We propose the use of a portable, instrument-free platform that can use direct patient blood samples to render a diagnostic readout. These kinds of technologies are analogous to the common pregnancy test lateral flow assay and allow for the monitoring of severe infection at the point-of-care, as well as provide a means of translating clinical assays into the hands of users.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
467005
Name
Shafique Houda
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a serological microfluidic assay for the rapid detection of interferons in COVID-19 patients
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
3d Printing; Autoantibodies; Biomedical Engineering; Capillary Circuits; Chain Reaction; Covid-19; Elisa; Microbead Assays; Microfluidics; Serology
Abstract
Antibodies are a natural immune response developed by the body to protect against infection, but in some cases, individuals can develop autoantibodies that attack components of the individual's own body. As such, a dysfunctional immune response can result in an increased susceptibility to infection. In the case of COVID-19 patients, autoantibodies that attack immune system's hormones, like interferons, can result in life-threatening and critical COVID-19 infections. Therefore, the detection of these autoantibodies is critical in managing a patient's prognosis and monitoring for critical infections to protect those at the highest risk. Current testing methods are done in batch groupings and lack accessibility. We propose the use of a portable, instrument-free platform that can use direct patient blood samples to render a diagnostic readout. These kinds of technologies are analogous to the common pregnancy test lateral flow assay and allow for the monitoring of severe infection at the point-of-care, as well as provide a means of translating clinical assays into the hands of users.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shafique, Houda
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~